A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

• ClinicalTrials.gov Identifier: NCT05335993
• Recruitment Status: Recruiting
• First Posted: April 20, 2022
• Last Update Posted: July 28, 2022
• Sponsor: CanariaBio Inc.
• Collaborator: Veristat, LLC
• Information provided by (Responsible Party): CanariaBio Inc.

Study Description

Brief Summary:

Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.

Condition or disease	Intervention/treatment	Phase
Recurrent Ovarian Cancer; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Ovarian Cancer; Recurrent Fallopian Tube Cancer; Peritoneal Cancer; Recurrent Carcinoma of Ovary; Adenocarcinoma of Ovary	Biological: Oregovomab; Drug: Niraparib	Phase 2

Detailed Description:

Phase 2 single arm open label study to evaluate the combination of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer. Approximately 15 subjects will be screened to enroll approximately 10 evaluable subjects.

The study will include:

• Screening period up to 28 days prior to start of study treatment.
• Treatment period up to 24 weeks.
• Post-treatment follow-up period:
• Safety Follow-up: all subjects will be followed at least 30 days after end of treatment for safety.
• Long Term Follow-up: all subjects will be followed for survival approximately every 3 months for 1 year, until death, withdrawal of consent, lost to follow-up, or sponsor decision to close the study; or whichever comes first.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
• Actual Study Start Date: July 25, 2022
• Estimated Primary Completion Date: May 30, 2023
• Estimated Study Completion Date: May 30, 2023

Arms and Interventions

Arm

Intervention/treatment

Experimental: Combination of Oregovomab and Niraparib; Niraparib (300/200 mg) will be administered orally once daily.; Oregovomab (2 mg) will be administered via IV infusion on Day 1 of Week 1, Week 4, Week 7, Week 12, and Week 20.

Biological: Oregovomab; 2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.; Other Names: MAb-B43.13; Monoclonal antibody B43.13; Drug: Niraparib; 300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is <77 kg or platelet count is <150,000 μL, the daily dosing will be 200mg.; Other Name: Zejula

Outcome Measures

Primary Outcome Measures :

1. Assessment of Disease Control Rate (DCR) [ Time Frame: At 12 weeks ]
   To evaluate anti-tumor activity of oregovomab added to niraparib by Disease Control Rate, defined as the portion of subjects with complete response (CR), partial response (PR) and stable disease (SD) at week 12. The DCR will be determined as defined by RECIST 1.1
2. Assessment of Disease Control Rate (DCR) [ Time Frame: At 24 weeks ]
   To evaluate anti-tumor activity of oregovomab added to niraparib by Disease Control Rate, defined as the portion of subjects with complete response (CR), partial response (PR) and stable disease (SD) at week 24. The DCR will be determined as defined by RECIST 1.1

Secondary Outcome Measures :

1. To Establish the Preliminary Safety and Tolerability of Oregovomab When Added to Niraparib. [ Time Frame: Up to 30 days post last End of Treatment ]
   Frequency of adverse events (AEs), serious adverse events (SAEs), deaths and AEs leading to discontinuation of treatment as defined by CTCAE version 5.0.
2. To Establish the Preliminary Safety and Tolerability of Oregovomab When Added to Niraparib. [ Time Frame: Up to week 24 ]
   A. Change in baseline from week 1 to week 24 the frequency of vital signs taken.
3. To Establish the Preliminary Safety and Tolerability of Oregovomab When Added to Niraparib. [ Time Frame: Up to week 24 ]
   Change in baseline from week 1 to week 24 the severity of vital sign measurements.
4. To Establish the Preliminary Safety and Tolerability of Oregovomab When Added to Niraparib. [ Time Frame: At week 7 ]
   Humoral immune response measured by HAMA at week 7 relative to baseline.

Other Outcome Measures:

1. Progression-Free Survival (PFS) [ Time Frame: Baseline up to two years ]
   Defined as date of first dose of study treatment to the date of event defined as the first documented progression as per RECIST v1.1
2. Overall Survival (OS) [ Time Frame: Baseline up to two years ]
   Defined as the portion of subjects who survive for 24 months after first dose.
3. Overall Response Rate (ORR) [ Time Frame: Week 12 to Week 24 ]
   Overall Response Rate (ORR) to alternate next-line therapy-initiated post Week 12 measured at Week 24 relative to their Week 12 assessment ((new baseline).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Women 18 years of age and older.
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subjects with CA125-associated recurrent epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin.
2. Subjects must have histologically diagnosed high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and experienced a response lasting at least 6 months to first-line platinum-based therapy.
3. Previously treated disease with up to 3 prior lines of therapy, including at least one platinum-based therapy. Each line of therapy should have been changed due to recurrence, progression, or toxicity. Maintenance therapy with bevacizumab, hormonal therapies and / or a PARP inhibitor is not considered a line of therapy.
4. Must have received prior platinum-based chemotherapy for first line ovarian cancer, however they must have been platinum sensitive for ≥6 months after the most recent platinum-containing regimen prior to the start of study treatment.
5. Must have medical assessment consistent with prognosis for an expected survival of at least 6 months and be clinically appropriate to receive a 12-week hiatus from any cytotoxic treatment according to the best clinical judgement of the treating Investigator.
6. Must have had an elevated serum CA125 >50 units / mL measured at screening within 28 days of start of study treatment.
7. Must have measurable disease, including identification of marker lesions, by radiographic or physical criteria suitable for evaluation according to RECIST v1.1 for documentation of disease response or progression.
8. Must have an ECOG Performance Status of 0, 1 or 2.

9. Must have adequate organ function defined as:

   1. Absolute neutrophil count ≥1,500 / μL
   2. Platelets ≥100,000 / μL
   3. Hemoglobin ≥9 g / dL
   4. Total bilirubin ≤1.5 x ULN (≤2.0 x ULN in subjects with known Gilberts syndrome) OR direct bilirubin ≤1 x ULN
   5. LDH, SGOT and SGPT<2.5 x ULN
   6. Albumin >3.5 g / dL
   7. Serum Creatinine < 1.5 mg/dL
10. For women of childbearing potential, a negative pregnancy test and willingness to avoid pregnancy by using a highly effective method of contraception from the first dose of study treatment to 6 months after last dose of study treatment.
11. Able to take oral medications.
12. Sign informed consent and authorization permitting release of personal health information.

Exclusion Criteria:

1. Subject must not be simultaneously treated in any interventional clinical trial.
2. Subject must not have had major surgery ≤3 weeks prior to initiating protocol therapy and subject must have recovered from any surgical effects.
3. Subject must not have received investigational therapy ≤4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy.
4. Subject has had radiation therapy encompassing >20% of the bone marrow within 2 weeks;
5. Subject must not have received a transfusion (platelets or red blood cells) ≤2 weeks prior to first dose of study treatment.
6. Subject must not have received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior to initiating protocol therapy.
7. Subject has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted >4 weeks and was related to the most recent treatment.
8. Subject must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection or active infection causing fever. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent. Subjects with chronic diseases that are well controlled (e.g., diabetes mellitus, hypertension [<140 sBP and <90 dBP]) are eligible.
9. Evidence of clinically significant cardiovascular and respiratory conditions including myocardial infarction within 1 year, uncontrolled or unstable angina, congestive heart failure (New York Heart Association Class III or IV), arrhythmia (Grade 2 or higher), chronic obstructive pulmonary disease, persistent asthma, or a history of asthma within 5 years.
10. Subject must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
11. Diagnosed or treated for another malignancy within 5 years before the first dose, or previously diagnosed with another malignancy and have any evidence of residual disease. Subjects with non-melanoma skin cancer or cervix carcinoma in situ are not excluded if they have undergone complete resection.
12. Subject must not have known, symptomatic brain or leptomeningeal metastases.
13. Have an active autoimmune disease (e.g., rheumatoid arthritis, SLE, ulcerative colitis, Crohn's Disease, MS, ankylosing spondylitis, thyroiditis) requiring continuing immune suppressive therapy.
14. Recognized immunodeficiency condition including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary, or congenital immunodeficiency's (HIV infection, see below).
15. Chronically treated with systemic doses of immunosuppressive drugs such as cyclosporine, methotrexate, adrenocorticotropic hormone (ACTH) or immune suppressive monoclonal antibodies.
16. Chronic therapeutic corticosteroid use, defined as >5 days of prednisone or equivalent, with the exception of inhalers or those on a pre-planned steroid taper. (Note: Premedication with corticosteroids per institutional standard of care is allowed).
17. Any previous treatments with oregovomab.
18. Known allergy to murine proteins or hypersensitivity to oregovomab, niraparib, or any of the excipients of oregovomab or niraparib.
19. Have contraindications to the use of pressor agents (e.g., SC epinephrine), notably monoamine oxidase inhibitor (MAOI) use.

20. Any of the following conditions (on-study testing is not required):

    1. Known HIV-infected subjects unless on effective anti-retroviral therapy with an undetectable viral load within 6 months, or
    2. Known or suspected hepatitis B if active infection (subjects with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or
    3. Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load).
21. Unable understand, and / or unwilling to sign a written consent form which must be obtained prior to treatment.

Contacts and Locations

Contacts

Contact: Clinical Operations; 1-780-448-1400; ClinicalTrialDisclosures@oncoquestinc.com

Locations

United States, North Carolina

Duke Cancer Center; Recruiting

Durham, North Carolina, United States, 27710

Contact: Angeles Secord, MD 916-533-1603 angeles.secord@duke.edu

Principal Investigator: Angeles Secord, MD

United States, Oklahoma

Stephenson Cancer Center- University of Oklahoma Health Sciences Center; Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contact: Debra C Richardson, MD 405-271-8707 Debra-Richardson@ouhsc.edu

Principal Investigator: Debra Richardson, MD

United States, Virginia

University of Virginia Health System; Recruiting

Charlottesville, Virginia, United States, 22903

Contact: Linda Duska, MD 434-924-9333 LRD5D@virginia.edu

Principal Investigator: Linda Duska, MD

Sponsors and Collaborators

CanariaBio Inc.

Veristat, LLC

Investigators

• Study Director: Sunil Gupta, MD, FRCPC; CanariaBio Inc.

More Information

• Responsible Party: CanariaBio Inc.
• ClinicalTrials.gov Identifier: NCT05335993
• Other Study ID Numbers: QPT-ORE-004
• First Posted: April 20, 2022
• Last Update Posted: July 28, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Recurrence; Disease Attributes; Pathologic Processes; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases; Gonadal Disorders; Fallopian Tube Diseases; Niraparib; Oregovomab; Poly(ADP-ribose) Polymerase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Immunological